ELISA and indirect immunofluorescence tests (IIFT) have been developed for sensitive and specific detection of antibodies against Zika virus in patient serum samples. The assays are suitable for diagnosing acute infections as well as for disease surveillance. In particular, serological analyses can aid the differentiation of infections with Zika virus, dengue virus and chikungunya virus, which manifest with similar symptoms and are endemic in much the same geographic regions. Anti-Zika Virus ELISA (IgM or IgG) are based on highly specific recombinant Zika NS1 protein which avoids cross reactivity with other flaviviruses. Data from panels of well characterized sera have confirmed that there is no cross reactivity with flaviviruses including dengue, West Nile, yellow fever and Japanese encephalitis viruses. In studies on clinically and serologically characterized samples the IgM and IgG ELISA showed 100% sensitivity and 100% specificity. Anti-Zika Virus IIFT (IgM or IgG) utilize Zika virus-infected cells as the antigenic substrate. Positive and negative results are evaluated by fluorescence microscopy. With the Arboviral Fever Mosaic 2 the Zika virus substrate is incubated in parallel with substrates for chikungunya virus and dengue virus serotypes 1 to 4. This BIOCHIP combination can help in the differential diagnosis of Zika, dengue and chikungunya virus infections. Due to the use of whole virus particles, cross reactivities between flavivirus antibodies can occur. Serological tests provide a longer window for diagnosis than direct detection methods, which are only effective during the viremic phase within the first week after onset of symptoms. Detection of specific IgM or a significant rise in specific IgG in a pair of samples taken seven to ten days apart is evidence of an acute infection. Serological analyses are also important for prenatal monitoring, screening of donated blood and epidemiological studies. Zika virus is the pathogenic agent of Zika fever, an infectious topical disease which manifests with fever, exanthema and arthritis. Zika virus infection has been linked to congenital malformations, in particular microcephaly, and neurological complications such as Guillain-Barré syndrome. The virus is transmitted by mosquitoes of the Aedes family. Zika virus is currently spreading explosively in the Americas.
Read more

The Acusera Liquid Cardiac Control is designed with ease of use and convenience in mind.  The liquid ready-to-use format eliminates problems with reconstitution making it ideal for both the clinical laboratory and point of care testing. With method and instrument specific target values provided for an impressive 10 cardiac markers including BNP, NT-ProBNP, D-dimer and Homocysteine effective consolidation and flexibility is guaranteed. 

• Liquid ready-to-use
• 100% human serum providing a matrix similar to the patient sample
• Three levels of control available spanning the complete clinical range
• Low levels of Troponin I and T in the level 1 control
• Third party control providing an independent, unbiased assessment of performance
• Open vial stability of 30 days at +2-8^oC for all analytes

Read more

A new series of controls for use with highly sensitive nucleic acid assays, ACCURUN 341 Nucleic Acid Positive controls for Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG) are designed to monitor and validate molecular diagnostic test performance. The controls are prepared with elementary bodies derived from cultured Chlamydia trachomatis and cultured colony-forming units of Neisseria gonorrhoeae. This whole organism design closely simulates an actual patient sample, challenging every stage of the assay from sample extraction through amplification and detection. The controls do not require reconstitution or dilutions that could possibly introduce contamination or variation into the assay. They are specially designed for use on the four most popular platforms currently on the market. Instrument-specific vials allow the controls to be placed directly in the test platform.
Read more

The Toxoplasma gondii IgG Avidity EIA test from Ani Labsystems has been updated. New T. gondii IgM EIA and IgG EIA tests have also been developed to form a full Toxo package. The new T. gondii IgM EIA is a capture test that can be run simultaneously with the new T. gondii IgG EIA. The T. gondii IgG EIA test provides quantitative results, and automatically generates the guidelines for the avidity assay, which needs only two dilution points. The T. gondii IgG Avidity EIA kit contains avidity wash buffer and avidity controls, and the kit is sold as a convenient supplementary package to the IgG test. The strips of kits have been individually labelled for easy identification. The tests can be automated or run manually.
Read more